Share Talk - Exclusive Stock Market News and Articles
Zak Mir talks to Adrian Kinkaid, CEO Fusion Antibodies
December 5, 2023
Fusion Antibodies plc (AIM: FAB), as the Early Discovery Contract Research Organisation specialising in pre-clinical antibody discovery, announces its unaudited interim results for the six months ended 30 September 2023 and provides an update on recent commercial progress.